Please login to the form below

Not currently logged in
Email:
Password:

S-A to enter Japanese generic drug market

Sanofi-aventis will form a generic drug venture with Nichi-Iko Pharmaceutical to enter Japan's generic drug market

Sanofi-aventis (S-A) will form a generic drug venture with Nichi-Iko Pharmaceutical to enter Japan's generic drug market.

S-A will pay Nichi-Iko $48.4m for a 4.7 per cent stake in the Japanese drug maker and hold a 51.0 per cent stake in the venture to sell S-A's insomnia drug Amoban (zopiclone) in Japan's $97bn drug market.

Nichi-Iko generated sales of 54.8bn Japanese yen ($601m) in 2009.

Olivier Charmeil, S-A's senior vice president, Asia Pacific & Japan commented on the venture: "It will allow us to strengthen our leadership and develop a strong presence in the fast growing generic market in Japan."

The venture aims to capitalise on the Japanese government's push to increase usage of generic drugs. It aims to increase generic share in the total pharmaceutical market from its current 20 per cent to 30 per cent by 2012.

S-A has been steering away from focusing on blockbuster drugs, which are increasingly difficult to develop and are vulnerable to patent challenges. It has been seeking to expand into areas such as generics, consumer health and emerging markets.

After the announcement of the venture, Nichi-Iko shares were up 1.2 per cent.

1st June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics